Verrica Pharmaceuticals Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
Verrica Pharmaceuticals Inc. entered into a credit agreement dated August 3, 2026 with PD Joint Holdings, LLC Series 2016-B as lender. The initial term loan commitment is $12.5M with a maturity date of December 31, 2030. The commitment increases to $27.5M if Milestone Conditions are achieved (YCANTH revenue targets, DAU growth, gross margin, operating expenses, Nasdaq listing, FDA clearance, no defaults/MAE). Interest accrues via PIK (paid-in-kind) at 8% base margin, stepping down to 7.5% or 7% upon achieving rate-step-down conditions. A final payment fee of 16% IRR is due upon liquidity event.
Why this rating
Significant financing for micro-cap ($27.3M) pharma company. Loan is material relative to company size (~46% of market cap). Terms are onerous (8% + SOFR floor, PIK interest, 1% prepay fee, 16% IRR final payment), suggesting lender-friendly structure. Provides runway but heavily dependent on YCANTH commercialization hitting aggressive thresholds.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.